Angelo Markatos, DO
Nephrology · Brick, NJNPI 1447279245
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 278 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 28.8% of the total.
Across 278 payments — averaging $23.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Vifor Pharma, Inc.$1K
- Bayer$475
- Ardelyx, Inc.$431
- Otsuka America Pharmaceutical, Inc.$328
- GSK$286
- plus $2K from 21 others
What the payments were for
- Food & beverage$6,43799%
- Education$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 67 | $1,867 |
| Vifor Pharma, Inc. | 47 | $1,028 |
| Bayer | 21 | $475 |
| Ardelyx, Inc. | 14 | $431 |
| Otsuka America Pharmaceutical, Inc. | 18 | $328 |
| GSK | 14 | $286 |
| Boehringer Ingelheim | 9 | $243 |
| OPKO Pharmaceuticals, LLC | 9 | $236 |
| Amgen(2 entities) | 13 | $208 |
| Novartis | 10 | $166 |
| Daiichi Sankyo Inc. | 10 | $143 |
| W. L. Gore & Associates, Inc. | 1 | $143 |
| Calliditas Therapeutics US Inc. | 2 | $131 |
| Lemaitre Vascular, Inc. | 1 | $128 |
| Fresenius USA Marketing, Inc. | 7 | $114 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 | $100 |
| Lilly USA, LLC | 5 | $84 |
| Aurinia Pharma U.S., Inc. | 4 | $77 |
| Travere Therapeutics, Inc. | 4 | $65 |
| Akebia Therapeutics Inc | 5 | $53 |
| Scpharmaceuticals Inc. | 2 | $46 |
| Ascendis Pharma Endocrinology Inc | 2 | $35 |
| Shire North American Group Inc | 2 | $29 |
| Sanofi | 1 | $23 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Corcept Therapeutics | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$449
- Veltassa$323
- FARXIGA$250
- XPHOZAH 30 MG$250
- ACUSEAL Vascular Graft$143
- ARTEGRAFT VASCULAR GRAFT$128
- TARPEYO$114
- Rayaldee$108
- BENLYSTA$108
How this compares
$6,480 in reported general payments places this provider in the 85th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 170 | $178,400 |
| JardianceEmpagliflozin | 53 | $50,487 |
| KerendiaFinerenone | 40 | $50,002 |
| VeltassaPatiromer Calcium Sorbitex | 49 | $45,060 |
| LokelmaSodium Zirconium Cyclosilicate | 20 | $19,156 |
| Cinacalcet Hcl | 32 | $12,160 |
| Valsartan | 145 | $4,954 |
| Potassium Citrate ErPotassium Citrate | 41 | $4,343 |
| Nifedipine ErNifedipine | 97 | $4,131 |
| Chlorthalidone | 223 | $3,799 |
| NorvascAmlodipine Besylate | 11 | $3,756 |
| Calcitriol | 165 | $3,422 |
| Paricalcitol | 32 | $3,300 |
| Torsemide | 166 | $2,628 |
| Amlodipine Besylate | 254 | $1,531 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,867 | $197,556190 claims |
| Boehringer IngelheimJardiance | $243 | $50,48753 claims |
| BayerKerendia | $475 | $50,00240 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Brick
- Joseph AlbaneseBrick$41K
- Robert BrunoBrick$9K
- Winicjusz PaleckiBrick$8K
- John DepalmaBrick$7K
- Rajat KapoorBrick$6K
- Daniel BrouderBrick$5K
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.